7 loss years were recorded (limit 2), and average operating margin was negative (must be zero or higher), and margins varied 89.3% around their average (limit 35%).
- 7y median
- -3.9%
- Worst year
- -15.2%
- Latest · 2025
- 0.4%
# Alignment Healthcare LLC (ALHC.US) Canonical: https://gigainvestors.com/s/ALHC Analysis as of: 2026-10-16T07:26:22.919Z. Financial observations: FY2019–FY2025. Listing currency: USD. Reporting currency: USD. ## Verdict Not a wonderful business Quality tests for Buy: not passed (profit record: fail; earnings resilience is evidence only). Published buy qualification: no. Share price: $8.15 per share; close as of 2026-10-15. ## Checklist ### understandable: fail - 0 revenue declines in the last 10 years (informational) - more than 2 net loss years - negative average operating margin - operating margin variation exceeds 0.35 - Financial history: 7 years - Years with declining revenue: 0 - Years with a net loss: 7 - Operating margin variation: 0.89× Chart: Operating margin; fiscal year observations. - FY2019: -0.04× - FY2020: -0.01× - FY2021: -0.15× - FY2022: -0.09× - FY2023: -0.07× - FY2024: -0.04× - FY2025: 0.00× ### moat: fail - Years with nonpositive invested capital use equity plus debt and leases; positive earnings with no positive capital are shown above 100%. - ROIC median below threshold - ROIC worst years below threshold (more than 1 bad year allowed) - ROIC, median of available years: -25.2% - ROIC, second-lowest year: -30.8% - Typical minus recent gross margin: 1.3 pp - Typical gross margin (annual median): 12.4% - Recent gross margin (lower of latest and 3-year median): 11.0% - Years with nonpositive capital: 7 - Capital spending / revenue: 1.6% - ROIC including acquisitions, ten-year median: -820.9% Chart: ROIC excluding acquisitions; fiscal year observations. - FY2019: -39.3% - FY2020: -2.2% - FY2021: -30.3% - FY2022: -25.2% - FY2023: -30.8% - FY2024: -18.7% - FY2025: 2.3% ### economics: fail - owner earnings cash conversion below threshold - Cash conversion uses consolidated totals: No - Owner earnings, five-year total: -$619M - Net income, five-year total: -$622M - Return on incremental invested capital: >100% - Working capital / revenue, annual change: 0.9 pp Chart: Owner earnings · five years; fiscal year observations. - FY2021: -$195M - FY2022: -$150M - FY2023: -$149M - FY2024: -$128M - FY2025: $3.0M ### management: fail - potential debt-funded buybacks (informational) - buybacks unrelated to price (informational) - ROIC first 3 years vs last 3 years: -30.3% vs -18.7% - Per-share earnings: -0.30 to -0.67 (three-year endpoint medians) - per-share value declined or ends nonpositive - Management verdict uses per-share economic progress: Yes - Ordinary dilution, 5-year annual growth: 4.2% - Diluted shares, 5-year annual growth: 4.2% - Per-share value change: -$0.37 - Per-share value, starting three-year median: -$0.30 - Per-share value, ending three-year median: -$0.67 - Buybacks concentrated in cheaper years (correlation): -1.00 - Average buyback yield: 0.0% - Buyback history: 2 years - Debt-funded buybacks: Yes - ROIC, first three-year median: -30.3% - ROIC, last three-year median: -18.7% Chart: Earnings per share; fiscal year observations. - FY2019: -$0.30 - FY2020: -$0.14 - FY2021: -$1.07 - FY2022: -$0.83 - FY2023: -$0.79 - FY2024: -$0.67 - FY2025: -$0.00 ### accounting: pass - stock compensation exceeds 15% of operating cash flow - Sloan accruals: -13.2% - Receivables to sales index (DSRI): 1.13× - Restructuring years, last five: 0 - Stock compensation / operating cash flow: 44.4% - Earnings backed by cash: Yes - Accounting red flags: 1 - Goodwill and intangibles / equity: 0.20× Chart: Sloan accruals; fiscal year observations. - FY2019: -27.9% - FY2020: -9.0% - FY2021: -18.5% - FY2022: -16.4% - FY2023: -15.0% - FY2024: -20.8% - FY2025: -13.2% ## Holders ## Price story Down 66% since Jun 2026 · "ALHC is expanding quickly while showing better medical-cost control and higher profitability." (finance.yahoo.com, Aug 2026) · sales +46.1% Story as of 2026-10-16T09:58:16.400Z; price observation 2026-10-15. ### Sales · FY2024–2025 sales +46.1%; source https://www.sec.gov/Archives/edgar/data/1832466/000162828026012545/alhc-20251231.htm; observed 2026-02-27. - FY2019: $757M - FY2020: $959M - FY2021: $1.2B - FY2022: $1.4B - FY2023: $1.8B - FY2024: $2.7B - FY2025: $3.9B ### Gross margin · FY2025 gross margin 12.4%; source https://www.sec.gov/Archives/edgar/data/1832466/000162828026012545/alhc-20251231.htm; observed 2026-02-27. - FY2019: 12.6% - FY2020: 17.3% - FY2021: 11.0% - FY2022: 12.8% - FY2023: 11.0% - FY2024: 11.0% - FY2025: 12.4% ## Owner memo Memo as of 2026-10-16T08:06:05.509Z. ### How it makes money Operates in healthcare plans; annual sales are USD 3.9 billion. - Source: https://www.sec.gov/Archives/edgar/data/1832466/000162828026012545/alhc-20251231.htm (filed 2026-02-27); FY2025: revenue 3948719000; grossProfit 488563000; margin = grossProfit / revenue. ### Why customers stay Margins ranged from 11% to 12.4% during 2023–25; it lost 25.2% on its capital. - Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-27); FY2023: grossProfit / revenue = 11%. - Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-27); FY2024: grossProfit / revenue = 11%. - Source: https://www.sec.gov/Archives/edgar/data/1832466/000162828026012545/alhc-20251231.htm (filed 2026-02-27); FY2025: grossProfit / revenue = 12.4%. - Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-27); 7-year return on capital observations [[2019,-0.3931465415386693],[2020,-0.022468359902728992],[2021,-0.30342161398513917],[2022,-0.25234231214274716],[2023,-0.3081027238636329],[2024,-0.18696302148147112],[2025,0.02289963059026959]]; median -0.25234231214274716. ROIC follows the displayed moat series; financial companies use return on tangible equity. ### Can it raise prices Kept about a 13% gross margin through 2022 cost inflation. - Source: https://www.sec.gov/Archives/edgar/data/1832466/000162828026012545/alhc-20251231.htm (filed 2026-02-27); Gross margin observations: [[2021,0.11023717794468617],[2022,0.12849342367199174],[2023,0.11023617729473632]]; range within 2 percentage points. ### Where the cash goes Paid dividends in 1 of 7 years. - Source: https://www.sec.gov/Archives/edgar/data/1832466/000162828026012545/alhc-20251231.htm (filed 2026-02-27); FY2025: growth capex 0; upkeep 26781000; owner earnings 2977000. Growth capex / owner earnings = 0. - Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-27); Dividend observations: [[2019,54146000],[2020,0],[2021,0],[2022,0],[2023,0],[2024,0],[2025,0]]. Zero only counted when supported by a complete cash-flow statement. ### Are managers owners Insiders own 2.6% of the company. - Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-10-15); ALHC.US SharesStats.PercentInsiders = 2.568 percentage points; cache date 2026-10-15. ### What the price says The price is 0.4 times annual sales. - Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-02-27); Closing price 8.15 USD; reporting-to-trading FX 1; FY2025 annual sales per share 19.94239918205396; price multiple 0.4086770064924853. FY2025 cash earnings/share 0.01503488153119395. Closing-price date 2026-10-15. ## Monthly share-price history (USD per share) - 2021-03: $21.93 per share - 2021-04: $26.54 per share - 2021-05: $25.23 per share - 2021-06: $23.37 per share - 2021-07: $20.83 per share - 2021-08: $17.67 per share - 2021-09: $15.98 per share - 2021-10: $19.86 per share - 2021-11: $16.21 per share - 2021-12: $14.06 per share - 2022-01: $7.60 per share - 2022-02: $8.44 per share - 2022-03: $11.23 per share - 2022-04: $9.61 per share - 2022-05: $10.68 per share - 2022-06: $11.41 per share - 2022-07: $14.68 per share - 2022-08: $15.21 per share - 2022-09: $11.84 per share - 2022-10: $13.24 per share - 2022-11: $13.30 per share - 2022-12: $11.76 per share - 2023-01: $12.35 per share - 2023-02: $9.94 per share - 2023-03: $6.36 per share - 2023-04: $6.29 per share - 2023-05: $5.87 per share - 2023-06: $5.75 per share - 2023-07: $6.21 per share - 2023-08: $5.84 per share - 2023-09: $6.94 per share - 2023-10: $6.88 per share - 2023-11: $7.50 per share - 2023-12: $8.61 per share - 2024-01: $6.70 per share - 2024-02: $6.00 per share - 2024-03: $4.96 per share - 2024-04: $5.15 per share - 2024-05: $7.88 per share - 2024-06: $7.82 per share - 2024-07: $8.74 per share - 2024-08: $9.01 per share - 2024-09: $11.82 per share - 2024-10: $12.40 per share - 2024-11: $12.61 per share - 2024-12: $11.25 per share - 2025-01: $15.39 per share - 2025-02: $15.69 per share - 2025-03: $18.62 per share - 2025-04: $17.72 per share - 2025-05: $15.37 per share - 2025-06: $14.00 per share - 2025-07: $13.78 per share - 2025-08: $16.36 per share - 2025-09: $17.45 per share - 2025-10: $16.86 per share - 2025-11: $19.21 per share - 2025-12: $19.75 per share - 2026-01: $22.53 per share - 2026-02: $19.22 per share - 2026-03: $17.62 per share - 2026-04: $22.54 per share - 2026-05: $15.32 per share - 2026-06: $23.81 per share - 2026-07: $14.85 per share - 2026-08: $13.40 per share - 2026-09: $8.16 per share - 2026-10: $8.15 per share ## Annual estimated value (USD per share) Historical values use today's bond yield for every fiscal year Historical values use today's FX rate into trading currency for every fiscal year Historical values use current restated fundamentals and current commodity classification; they are not point-in-time estimates ## Sources [Original 10-K filing](https://www.sec.gov/Archives/edgar/data/1832466/000162828026012545/alhc-20251231.htm); period 2025-12-31, filed 2026-02-27. Estimates depend on assumptions and are not guarantees or investment advice. Underlying data remains subject to its source licenses; public reading does not grant bulk redistribution rights.
ALHC · US
Not a wonderful business
4 quality tests fail. A lower price would not fix the business.
7 loss years were recorded (limit 2), and average operating margin was negative (must be zero or higher), and margins varied 89.3% around their average (limit 35%).
Capital return excluding acquisitions: median -25.2% (minimum 15%), and the second-worst year -30.8% (minimum 10%).
Owners received -618.9 million over five years (must be positive).
Per-share value fell from -0.3 to -0.67, comparing three-year medians at each end (must rise and stay positive).
Profits were backed by cash: accruals were -13.2% of assets (limit 10%).
Profit record · fail 7 loss years in 7 (at most 2), mean operating margin -5.6%, three-year average owner earnings per share -0.49 USD. 7 loss years in the last 10; at most 2 allowed. Mean operating margin over the last ten years is negative. Three-year average owner earnings per share is not positive.